Paxlovid and COVID

The New England Journal of Medicine has been a leader in publishing recent studies on Paxlovid for COVID-19.

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

JAMA:

Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 InfectionThe STOP-PASC Randomized Clinical Trial